Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ave a buy order here at market price and won't execute?
http://www.investegate.co.uk/Article.aspx?id=201202230700119430X
Were on the 25th feb last year and 2 days later they hit the years high being 38p...this rns will state company has done 65% better on them results...looks a no brainer on paper..
I would say................director buys in dec and jan at 22p
Finals In the morning, could see a nice rise thoughout the day....65% growth forcast...broker target 30p
Brewin Dolphin maintained its "buy" recommendation for Sinclair IS Pharma (SPH), with a target price of 30p. With the pharmaceuticals company reporting first half growth of 65%, including like-for-like sales up 9%, the broker expects EBITDA to break into positive ground, compared to a 1.3 million pound loss in 2010's comparable period. However, Brewin raises concern over the difficult economic environment in mainland Europe, which it estimates accounts for 50% of the group's sales and 80% of profitability. The shares flatlined at 22.75p
david - hello - there are many reasons a Company will dispose of a business - it does not have to automatically imply that its short of cash. This seems a very encouraging RNS - the Group will report a small profit at the EBITDA level for the period compared with a loss of £1.3 million reported for the same period last year.
Chris Spooner, CEO of Sinclair IS, commented: "I am pleased with the strong performance of the Company during the first half. We have continued to deliver on our strategy to focus on fewer, bigger brands and build strong strategic partnerships. We are making good progress to becoming a high growth, self-sustaining international specialty pharma business. The first wave of launches by Invida has been very promising and we continue to focus on striking additional multi-country, multi-product deals in emerging markets during the second half."
Commercial update During the first half Invida, the Company's partner for the Asia Pacific region, successfully launched two of Sinclair IS's leading dermatology brands; Atopiclair for atopic dermatitis (into seven markets) and Papulex for acne (into six markets). Invida has seen good demand for these products and initial sales have been encouraging. Invida will launch these products into other territories in the region during the second half. In-line with the Group's strategy to complement its proprietary sales infrastructure with selected co-promotion partners, Sinclair IS entered into exclusive promotion agreements with Therabel and Norgine in the first half, to market and commercialise Xclair, the Group's treatment for radiation dermatitis, in France and Spain respectively. As part of its strategy to focus on fewer, bigger brands during the period the Group disposed of Mysoline, a non-core product acquired from the merger with IS Pharma, for £11.1 million and used the cash to part fund the acquisition of Advanced Bio-Technologies, Inc. The acquisition gave Sinclair IS global ownership, excluding the US, to scar prevention and treatment product Kelo-cote®, a well-established, potentially high growth product, which is now Sinclair IS' second largest brand.
Trading update Revenues for the six months ended 31 December 2011 were approximately £23.4 million, compared to £14.1 million for the same period last year, an increase in excess of 65%, and in‐line with market expectations despite difficult trading conditions in our core European markets. Like‐for‐like revenues (excluding product acquisitions and disposals, licence fees and currency fluctuations) increased by 9% over the period driven by the focus on a smaller number of key brands and the initial launches by Invida of Sinclair IS products across the Asia-Pacific region. Revenues from the Flamma franchise, Kelo-cote, Atopiclair and Bio-Taches all grew strongly in the period. Unsurprisingly, pharmaceutical market volumes and pricing remain under significant pressure across European markets; we have also seen de-stocking by wholesalers in a number of our European operations during the period. While de-stocking has held back like for like revenue growth in the period we are encouraged to see prescription data which shows that underlying demand for our products, so far, remains strong. The first half year is the maiden reporting period for the enlarged Sinclair IS group following the merger with IS Pharma. The Group will report a small profit at the EBITDA level for the period compared with a loss of £1.3 million reported for the same period last year.
ondon, UK, 13 January 2012 Sinclair IS Pharma (AIM:SPH.L) ("Sinclair IS" or the "Group"), the international specialty pharma company, announces a trading update for the six months ended 31 December 2011 ahead of its interim results which will be announced on 23 February 2012. • Revenue for the first half grew by more than 65% to reach approximately £23.4 million • Like‐for‐like revenue growth of 9% for the period • Sinclair IS profitable at the EBITDA level for the first half • Continued focus on a smaller number of key brands, which management believes will be central to the Company's future success, including Flammazine and Kelo-cote • Disposal of non-core Mysoline and acquisition of ex-US rights for Kelo-cote®
http://www.investegate.co.uk/Article.aspx?id=201201130700104976V
Same coat just dyed a different colour. The Disposal of Mysoline implies they are short of cash
Sinclair Is Pharma (SPH) kept its "buy" rating from Singer Capital, with a 48p target price. The broker says that a new Irish distribution agreement with Fannin should help improve the pharmaceutical company's margin and allow it to focus on other areas of its European business. Additionally, Singer expects the merger with Is Pharma to result in further investment in the UK, leading to improved revenues and margins
Brewin Dolphin initiates buy on Sinclair Pharma, target price 37p.
your strong buy recommendation in Dec 2010 coincides exactly with the start of a steady slide to todays price. Petty sarcasm isn't clever, but probably your only response to anyone not hyping. Anyone else have any thoughts on the latest update? My own thoughts are that nothing has changed. The previous management group also achieved steady increases in revenue without making profits. The historical problem has always been that the company has not been able to increase revenues without increasing costs. The model of selling through distributors and then retailers means that by the time the product gets to the end user Sinclair makes a tiny fraction of the total available margin. The current strategy of placing more products with fewer distributors may be easier to administer, but doesn't reduce the number of steps to the end user. Like I said before, if no one ever buys a second tub of atopiclair then its always going to be a struggle. Another problem is that there hasn't been a lot of progress in changing the product profile. Flammazine was initiated by the previous management, kelocote seems to be the only new product apart from the acquired IS stuff. Losses may be reducing, and a small profit might be achieved in a year or two more, but it's difficult to see anything that will justify a market cap of 60-90 million. Has anyone here ever used a Sinclair product? Know anyone who has?
Singer Capital Markets commented on Sinclair Pharma (SPH). The broker notes that the group has been unable to change its registered name to Sinclair IS Pharma following the recent merger with IS Pharma, but, nevertheless, said this will have little material impact and reiterated its 48p intrinsic valuation on the business. Looking ahead, while noting the rapid change over the last two years, Singer added that the merger will add both a distinctive and valuable product portfolio and an important UK element to the business. The shares slipped 1.25p to 30p.
Singer Capital Markets commented on Sinclair IS Pharma (SPH), the international specialty pharmaceutical company. The broker notes that the business has changed rapidly over the last two years since the appearance of the "new and revitalised management team". The most recent evidence of this is the merger with IS Pharma, Singer added, which will add both a distinctive and valuable product portfolio and an important UK element to the business. Shares in Sinclair lost 1.25p to 31.25p.
incter
Sinclair and IS Pharm agree merger Date: Thursday 07 Apr 2011 LONDON (ShareCast) - Skin treatments supplier Sinclair Pharma and speciality drugs group IS Pharma have reached agreement on a merger that was announced in February. IS Pharma shareholders will receive 2.68 Sinclair shares for every one of their shares. The merger intends to combine Sinclair’s distribution operations in France, Germany, Italy and Spain with IS’s in Britain and Ireland to create “a strong European business with direct presence in the major markets and partnerships in emerging growth markets.”
Sinclair Pharma’s revenues increased by 28% to £14.1m in the half-year to December. Like-for-like revenues increased by 9%, while the operating loss reduced to £2.6m from £13.7m. “The recent announcement regarding a possible merger with IS Pharma demonstrates the board's intention to improve critical mass and create substantial shareholder value" Sinclair said.
haven't significantly changed anything imo. Same products, been through lots of distributors in the past, never caught on. Sinclair state that they have forgone licensing fees in exchange for marketing spend from Sunstar, and that the Invida will spend on marketing. In the States, Sunstar are up against BIG brand mouthwashes with HUGE marketing/advertising budgets. Invida looks like a decent company, but at the end of the day it's whether anyone ever wants a second tub of Atopiclair that matters. It makes sense to consolidate multiple products through multiple territory distributors to simplify the relationship management, but the distributor model is tough - even if you make it more efficient. Sinclair will capture only a fraction of the available margin. Volume is critical to drive revenue and profit, but you have to have great products to achieve the volume. In the long term, revenues and profits should improve, but keep in mind a very high market cap for a company that is yet to make a proper profit.
What do you think of the results?
lol, yes silence speaks volumes! However your a share holder, so are you still in this waiting for a change of direction? Or have you lost faith? and if so will you be selling at a loss? after all better to cut your losses rather than stay in a share going nowhere or some people would keep averaging down but again not always a good idea.....
anyone have any thoughts on these? I havent brought into sph but have been thinking about doing so, so any opinions will be appreciated